Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYNAVOY vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life is approximately 30–40 hours, supporting once-daily dosing. Steady-state is achieved within 2–3 weeks.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8; undergoes glucuronidation by UGT1A9.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily via bile into feces (approximately 77% of total clearance as unchanged drug and metabolites); renal excretion accounts for about 15% (less than 1% unchanged). A small amount is excreted in urine as metabolites.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Approximately 94–96% bound to plasma proteins, primarily albumin.
47% bound to human plasma proteins, primarily albumin.
Apparent volume of distribution is about 50 L (approximately 0.7 L/kg), indicating extensive tissue distribution.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Absolute oral bioavailability is approximately 70% under fasting conditions. Food does not significantly affect absorption.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min) not on hemodialysis, reduce dose to 75 mg orally twice daily (adults) or 75 mg/m2 per dose (pediatric, max 75 mg per dose). End-stage renal disease on hemodialysis: no data, consider risks vs benefits.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: reduce to 75 mg orally twice daily (adults) or 75 mg/m2 per dose (pediatric, max 75 mg per dose). Child-Pugh C: reduce to 50 mg orally twice daily (adults) or 50 mg/m2 per dose (pediatric, max 50 mg per dose).
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
For patients aged ≥28 days and <18 years with body surface area (BSA) ≥1.0 m2: 100 mg orally twice daily. For BSA <1.0 m2: 100 mg/m2 per dose (maximum 100 mg per dose) orally twice daily. Administer with or without food.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment recommended. Clinical studies included patients ≥65 years; no overall differences in safety or efficacy observed. Monitor for adverse effects due to potential age-related comorbidities and renal/hepatic function decline.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
None.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Cardiomyopathy: Assess left ventricular ejection fraction (LVEF) before initiation, monitor during treatment, and withhold or permanently discontinue based on severity.,Ocular toxicity: Monitor for retinal vein occlusion, retinal pigment epithelial detachment, and visual disturbances; conduct ophthalmic evaluations.,Dermatologic toxicity: Manage rash, acneiform dermatitis, and hand-foot skin reactions with supportive care; dose interruption or reduction may be required.,Gastrointestinal toxicity: Diarrhea, nausea, vomiting, and stomatitis are common; manage with antiemetics and antidiarrheals.,Venous thromboembolism (VTE): Monitor for signs and symptoms; discontinue if life-threatening VTE occurs.,Rhabdomyolysis: Monitor creatine kinase (CK) levels; withhold if CK elevation with muscle symptoms occurs.,Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential and males with female partners of childbearing potential to use effective contraception.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
None.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice if taking concomitant CYP3A4 substrates. No dietary restrictions required.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
LYNAVOY (ribociclib) is contraindicated in pregnancy. Based on its mechanism of action (CDK4/6 inhibition) and animal studies, it can cause fetal harm. First trimester: High risk of embryotoxicity and teratogenicity; avoid pregnancy. Second and third trimesters: Continued risk; not recommended. Women of childbearing potential must use effective contraception during therapy and for at least 3 weeks after last dose.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
It is unknown if LYNAVOY is excreted in human milk; however, ribociclib and its metabolites are present in rat milk. Due to potential serious adverse effects in nursing infants, breastfeeding is not recommended during treatment and for at least 3 weeks after the last dose. M/P ratio not available.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
LYNAVOY is contraindicated in pregnancy and no dose adjustment recommendations exist. If a patient becomes pregnant during treatment, discontinue LYNAVOY immediately. No pharmacokinetic data are available to guide dose changes during pregnancy.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
LYNAVOY (lutetium Lu 177 vipivotide tetraxetan) is a PSMA-targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer. Requires premedication with antiemetics. Monitor for myelosuppression, xerostomia, and renal toxicity. Ensure adequate hydration prior to infusion. Contraindicated in severe bone marrow suppression.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
You are receiving a radioactive drug that targets prostate cancer cells. You may experience dry mouth, nausea, or low blood counts.,Drink plenty of fluids before and after treatment to protect your kidneys.,Avoid close contact with pregnant women, infants, and children for a period of time as instructed by your healthcare team.,Use effective contraception during treatment and for several months after the last dose.,Report any signs of infection, bleeding, or unusual fatigue to your doctor immediately.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYNAVOY vs CLOLAR, answered by our medical review team.
LYNAVOY is a Antineoplastic Agent that works by LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYNAVOY and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYNAVOY is: LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYNAVOY and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYNAVOY is classified as Category C. LYNAVOY (ribociclib) is contraindicated in pregnancy. Based on its mechanism of action (CDK4/6 inhibition) and animal studies, it can cause fetal harm. First trimester: High risk o. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.